Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL41454 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Tartaric Acid SCHEMBL29368126 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL30692284 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL30692300 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL41453 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL9602705 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL7761628 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL11578818 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL5961178 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL1938732 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388888-A1 | PROTEIN FORMULATION | KAESLER NUTRITION GMBH (DE) | 2025-12-25 | — | — | US | claimed |
| EP-4557962-A1 | PROTEIN FORMULATION | Kaesler Nutrition GmbH (DE) | 2025-05-28 | — | — | EP | claimed |
| CN-119735928-A | PET plastic uptake sheet containing nano material | 湖南九东科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| EP-3995473-B1 | ACTIVE MASS FOR A PYROTECHNIC DUMMY TARGET BURNING AT HIGH WIND SPEED | DIEHL DEFENCE GMBH & CO KG (DE) | 2025-03-26 | — | — | EP | claimed |
| EP-3684887-B1 | ETCHING SOLUTION FOR SIMULTANEOUSLY REMOVING SILICON AND SILICON-GERMANIUM ALLOY FROM A SILICON-GERMANIUM/SILICON STACK DURING MANUFACTURE OF A SEMICONDUCTOR DEVICE | VERSUM MAT US LLC (US) | 2024-09-25 | — | — | EP | claimed |
| WO-2024017958-A1 | PROTEIN FORMULATION | KAESLER NUTRITION GMBH (DE) | 2024-01-25 | — | — | WO | claimed |
| EP-4309503-A1 | PROTEIN FORMULATION | Kaesler Nutrition GmbH (DE) | 2024-01-24 | — | — | EP | claimed |
| CN-117043600-A | Mycobacterium tuberculosis compositions and methods | 石万良 | 2023-11-10 | — | — | CN | claimed |
| CN-115159558-B | Precipitation method of rare earth carbonate | 冕宁县新盛源新材料科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-115159558-A | Precipitation method of rare earth carbonate | 冕宁县新盛源新材料科技有限公司 | 2022-10-11 | — | — | CN | claimed |
| EP-2699661-A1 | CALCIUM SEQUESTERING COMPOSITION | Rivertop Renewables, Inc. (US) | 2014-02-26 | — | — | EP | claimed |
| EP-2699660-A1 | CALCIUM SEQUESTERING COMPOSITION | Rivertop Renewables, Inc. (US) | 2014-02-26 | — | — | EP | claimed |
| US-20120295986-A1 | CALCIUM SEQUESTERING COMPOSITION | RIVERTOP RENEWABLES, INC. | 2012-11-22 | — | — | US | claimed |
| US-20120277141-A1 | CALCIUM SEQUESTERING COMPOSITION | SILICON VALLEY BANK | 2012-11-01 | — | — | US | claimed |
| WO-2012145688-A1 | CALCIUM SEQUESTERING COMPOSITION | RIVERTOP RENEWABLES, INC. (US) | 2012-10-26 | — | — | WO | claimed |
| WO-2012145690-A1 | CALCIUM SEQUESTERING COMPOSITION | RIVERTOP RENEWABLES, INC. (US) | 2012-10-26 | — | — | WO | claimed |
| US-6929686-B2 | Ink composition for inkjet recording | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2005-08-16 | — | — | US | claimed |
| EP-0573054-B1 | Method for solubilising milk for purposes of analysis | SIETZEMA MANAGEMENT EN BEHEER (NL) | 1999-01-20 | — | — | EP | claimed |
| EP-0437500-B1 | METHOD FOR PRODUCING LIGNIN-PEROXYDASE BY USING NON-PROLIFERATING CELLS OF $i(PHANEROCHAETE CHRYSOSPORIUM) | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 1993-07-14 | — | — | EP | claimed |
| US-4876688-A | CONTAINING A CHIRAL CARBON | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECETARY OF THE DEPARTMENT OF ENERGY (US) | 1989-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388888-A1 | PROTEIN FORMULATION | FABP2, S100A6, SI | TSHR 3808/4885TP53 3396/4885CYP2C9 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.